Literature DB >> 25911291

Reduced serum vitamin D levels in neuromyelitis optica.

Erdem Tüzün1, Özlem Küçükhüseyin, Murat Kürtüncü, Recai Türkoğlu, İlhan Yaylım.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25911291     DOI： 10.1007/s10072-015-2229-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  6 in total

Review 1.  New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease.

Authors:  Chen Hsing Lin; S Kadakia; Marianne Frieri
Journal:  Autoimmun Rev       Date:  2013-10-12       Impact factor: 9.754

2.  Low serum vitamin D levels and recurrent inflammatory spinal cord disease.

Authors:  Maureen A Mealy; Scott Newsome; Benjamin M Greenberg; Dean Wingerchuk; Peter Calabresi; Michael Levy
Journal:  Arch Neurol       Date:  2011-11-14

3.  Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus.

Authors:  Lauren L Ritterhouse; Sherry R Crowe; Timothy B Niewold; Diane L Kamen; Susan R Macwana; Virginia C Roberts; Amy B Dedeke; John B Harley; R Hal Scofield; Joel M Guthridge; Judith A James
Journal:  Ann Rheum Dis       Date:  2011-05-17       Impact factor: 19.103

4.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

5.  Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients.

Authors:  Laia Grau-López; Maria Luisa Granada; Dàlia Raïch-Regué; Mar Naranjo-Gómez; Francesc E Borràs-Serres; Eva Martínez-Cáceres; Cristina Ramo-Tello
Journal:  BMC Neurol       Date:  2012-09-24       Impact factor: 2.474

6.  Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability.

Authors:  Ju-Hong Min; Patrick Waters; Angela Vincent; Hye-Jin Cho; Byung-Euk Joo; Sook-Young Woo; Soo-Youn Lee; Hee-Young Shin; Kwang Ho Lee; Byoung Joon Kim
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240
  6 in total
  3 in total

1.  Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod.

Authors:  L Ferre'; F Clarelli; G Sferruzza; M A Rocca; E Mascia; M Radaelli; F Sangalli; G Dalla Costa; L Moiola; M Aboulwafa; F Martinelli Boneschi; G Comi; M Filippi; V Martinelli; F Esposito
Journal:  Neurol Sci       Date:  2018-05-13       Impact factor: 3.307

Review 2.  Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.

Authors:  Zhen Wang; Yaping Yan
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

Review 3.  Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.

Authors:  Priscilla Koduah; Friedemann Paul; Jan-Markus Dörr
Journal:  EPMA J       Date:  2017-11-15       Impact factor: 6.543
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.